Abstract PS1-12-18: Treatment with CDK4/6 inhibitors in elderly patients with HR positive/HER2 negative metastatic breast cancer: experience from a Spanish center

Clinical Cancer Research 2026

View at publisher
Authors: Mariana López Flores, M. Vázquez Diez, Jorge Alberto Fong Gutierrez, E. Honrado Franco, JC Sáez Hortelano, S. Abella Alvarez, M. Rodríguez García, L. López González, A. López González
DOI: 10.1158/1557-3265.sabcs25-ps1-12-18
Cited by: 0

Abstract

Abstract Introduction CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). However, evidence in elderly patients remains limited. This study aimed to evaluate the efficacy and tolerability of CDK4/6i in elderly (≥70 years) versus younger (

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS1–12
Publication date
17 February 2026
Language
EN